Lexicon Pharmaceuticals (Nasdaq: LXRX) announced it has completed patient enrollment in its pivotal Phase 3 SONATA-HCM clinical trial, which is ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE